Introduction
============

Bone homeostasis is maintained by osteoclast-mediated bone destruction and osteoblast-mediated bone formation, which are two tightly coupled and controlled processes. An imbalance between both bone resorption and formation can result in metabolic bone diseases such as osteoporosis ([@B23]). Therefore, agents for regulation of the balancing mechanisms are important for osteoporosis therapy. Many coupling factors have been identified for regulating the coordination of osteoblastogenesis and osteoclastogenesis. For example, differentiation and maturation of osteoclasts (derived from monocyte/macrophage precursor cells) can be regulated by osteoblasts, which express key osteoclast differentiation factors such as receptor activator of nuclear factor kappa-B ligand (RANKL; [@B32]). In addition, to counterbalance the activity of these stimulatory coupling factors, osteoblasts can produce inhibitory coupling factors, including osteoprotegerin, sclerostin, bone morphogenetic protein 6 (BMP6), and Wnt10b ([@B1]; [@B5]; [@B3], [@B4]).

Sema3A is a member of the semaphorin family, a group of proteins involved in the development of the nervous, immune systems and bone ([@B26]; [@B34]). Sema3A, produced by osteoblasts, has been identified as a potent and direct inhibitor of osteoclast formation from osteoclast precursor cells ([@B11]; [@B14]). Distinct from other coupling factors, Sema3A promotes osteoblast differentiation from bone marrow mesenchymal stem cells (the precursor of osteoblasts), indicating a dual function role in which it inhibits osteoclastogenesis and enhances osteoblastogenesis ([@B9]). The Sema3A signaling pathway is activated through binding with its cell-surface receptor composed of an Nrp1 and plexinA1 protein complex, which functions as a signal-transducing subunit ([@B13]; [@B34]). This complex induces different downstream signaling molecules in osteoclasts and osteoblasts, resulting in different regulatory effects on differentiation. Therefore, regulation of the Sema3A pathway in osteoclasts and osteoblasts would be promising for the bone remodeling balance and be helpful for the development of therapeutic agents.

Wedelolactone is a small molecular compound isolated from *Ecliptae herba.* In China, *Ecliptae herba* is used as an herbal kidney-nourishing drug and also is commonly believed to have the ability to strengthen bones. It is also used to treat bone diseases such as osteoporosis. Wedelolactone has been reported to possess various biological activities, including inhibition of 5-lipoxygenase and typsin, antagonizing myotoxins, and inducing caspase-dependent apoptosis ([@B33]; [@B24]; [@B29]; [@B28]). Recently, it was reported that *Ecliptae herba* extract showed a therapeutic effect on bone metabolism of ovariectomized rats ([@B36]). We previously reported that wedelolactone, as the major active constituent in *Ecliptae herba*, inhibited the proliferation and differentiation of osteoclastic RAW264.7 and mouse monocytes from blood ([@B21]).

In this study, we used wedelolactone-treated bone marrow mesenchymal stem cell (BMSC)-derived conditioned medium to treat osteoclastic RAW264.7 cells. The differentiation and bone resorptive activity of RAW264.7 cells was evaluated. Interestingly, compared to RANKL-treated alone, RAW264.7 cells exposed to conditioned media for 4 days showed a significant decrease in osteoclastic differentiation and function. The production of Sema3A from BMSC was evaluated. The role of wedelolactone-induced Sema3A/Plexin A1/NRP1 pathway in BMSC and in osteoclastic RAW264.7 cells was then subsequently investigated.

Materials and Methods {#s1}
=====================

Isolation and Culture of Mouse Bone Marrow Mesenchymal Stem Cells (BMSCs)
-------------------------------------------------------------------------

BMSC were isolated according to a previously published protocol with some modifications ([@B20]; [@B35]). Briefly, BMSC were isolated from bone marrow, which was aspirated from 8-week old BALB/c mice. All procedures involving mice were carried out in compliance with the relevant laws and institutional guidelines, and approved by the Ethics Committee at Dalian Medical University. BMSC were collected using gradient centrifugation of mesenchymal stem cell-specific gradient solutions (Tianjin Haoyang Biological Manufacture, China). A layer of the bone marrow cell fraction in phosphate-buffered saline (PBS) was placed on top of the gradient solution and centrifuged at 340 *g* for 20 min. The cell fraction was collected and washed with PBS after centrifugation. The cell samples were resuspended in Minimum Essential Medium Alpha Medium (α-MEM, Gibco, Paisley, UK), supplemented with 10% fetal calf serum (FCS), 100 U/ml penicillin, and 100 μg/ml streptomycin, and maintained at 37°C with 5% CO~2~ in a humidified atmosphere. On day 3, the cell suspension was replaced with fresh complete medium. BMSC were further separated from hematopoietic cells by their differential adhesion to tissue culture plastic and prolonged proliferation potential. After 6--7 days in culture, 90% confluence was reached. These cell samples were used in the experiment.

Conditioned Media Preparation
-----------------------------

BMSC were cultured with osteogenic medium (OS) (100 nM dexamethasone, 1 mM β-glycerophosphate, and 5 μM [L]{.smallcaps}-ascorbic acid 2-phosphate) [+]{.ul} 2 μg/ml wedelolactone. Wedelolactone was provided by Key Laboratory of Separation Science for Analytical Chemistry at Dalian Institute of Chemical Physics, Chinese Academy of Sciences (Dalian, China). The purity was \>98%. These cells were incubated for 12 days at 37°C with 5% CO~2~ in a humidified incubator. Every 3 days the medium was changed and collected. The 3-, 6-, 9-, and 12-day incubation fractions containing wedelolactone-treated or -untreated conditioned media were harvested for use.

Culture of Pre-osteoclastic RAW264.7 Cells
------------------------------------------

Mouse pre-osteoclastic RAW264.7 cells were purchased from the Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The cells were cultured in DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% FCS, 0.03% [L]{.smallcaps}-glutamine (Gibco), penicillin (100 U/ml), and streptomycin (100 μg/ml) and maintained at 37°C with 5% CO~2~ in a humidified atmosphere.

For differentiation, cells were plated in DMEM or conditioned medium supplemented with 30 ng/ml recombinant RANKL. For drug assays, wedelolactone was added to the culture medium at different concentrations. Cells were incubated for 4 days at 37°C with 5% CO~2~ in a humidified incubator and fed daily with RANKL-supplemented medium.

MTT Assay
---------

RAW264.7 cells were plated at a density of 1 × 10^4^ cells per well of 96-well plates. After overnight incubation, RANKL, wedelolactone, or conditioned media was added to the plates. Following incubation for 6 days, cell growth was measured by 3-(4, 5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT) with a plate reader (Tecan, Switzerland) as previously described ([@B21]). The percentage of proliferation was calculated with the formula:
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Measurement of TRAP Activity
----------------------------

RAW264.7 cells were fixed with 60% citrate buffered acetone for 30 s. The fixed cells were then washed with water 3× and were further incubated with 100 μl phosphatase substrate solution containing 10 mM pNPP and 10 mM sodium tartrate in 50 mM citrate buffer (PH 4.6) at 37°C for 1 h. After incubation, the enzyme reaction mixture was transferred to another plate, and the reaction was stopped with 100 μl of 0.1 N NaOH. Absorbance at 405 nm was measured using an ELISA reader (Tecan, Switzerland).

For staining of tartrate-resistant acid phosphatase (TRAP), cells were fixed with 60% citrate buffered acetone for 30 s. The cells were then stained for TRAP with 0.1 M acetate solution (PH 5.0) containing 6.76 mM sodium tartrate, 0.12 mg/ml naphthol AS-MX phosphate, and 0.07 mg/ml of fast Garnet GBC solution as described in the manufacturer's instruction (Sigma, St. Louis, MO, USA). Photomicrographs were obtained using an Olympus microscope at 200× magnification.

ALP Activity Assay
------------------

For *in vitro* osteoblast differentiation, mouse BMSC were isolated from 8-week old BALB/c mice according to a previously published protocol, and were cultured with α-MEM with 10% FBS. After 5 days, cells were reseeded (1 × 10^4^ per cm^2^) and cultured with OS. Culture medium was changed every third day. After 9 days, alkaline phosphatase (ALP) staining (Sigma) and activity measurements were performed by using an ALP staining kit according to manufactory's instruction.

Western Blot Analysis
---------------------

For Western blot analysis, cells were lysed using lysis buffer containing 10 mM Tris/HCl (PH 7.5), 150 mM NaCl, 2 mM EDTA, 1% (v/v) Triton X-100, 1 mM Na~3~CO~4~, 1 mM PMSF, and 0.1 mM aprotinin. The cells were scraped from the plates and centrifuged at 16,060 *g* for 30 min at 4°C. For nuclear protein extraction, the pellet from the 700 *g* centrifugation was washed by buffer A, resuspended in buffer B containing 20 mM HEPES, pH 7.9, 1.5 mM MgCl~2~, 420 mM NaCl, 0.2 mM EDTA, 10 mM NaF, 2 mM Na~3~VO~4~, 1 mM pyrophosphoric acid, and Complete TM protease inhibitors (Cell Signaling, USA) and incubated on ice for 5 min. The protein concentration in the cell lysates was determined using the Bradford protein assay. Western blot analysis was performed as previously described using the several antibodies ([@B3]). Sema3A, plexin A1, and NRP1 antibodies were obtained from ABcam, Cambridge, UK. PLCγ2, phospho-PLCγ2, β-cateinin, and DAP12 antibodies were from Cell Signaling, USA.

Immunoprecipitation Assay
-------------------------

For immunoprecipitation assay, cells were harvested and lysed in radioimmuno- precipitation assay (RIPA) buffer. Cell lysates were then centrifuged at 12,000 rpm for 10 min at 4°C ([@B14]). PlexinA1 or IgG antibodies were added into the supernatant and incubated at 4°C overnight with rotation. Protein A or G agarose beads (Thermo, Rockford, IL, USA) were then added and incubated with rotation for 3 h at 4°C. After centrifugation, proteins were subjected to Western blotting.

Quantitative Real-Time RT-PCR
-----------------------------

All work was carried out in a designated PCR-clean area. RNA was extracted from cells using Trizol reagent (Gibco-BRL, Rockville, MD, USA) and isolated as specified by the manufacturer. The RNA was DNAse-treated (DNase I-RNase-Free, Ambion) to remove any contaminating DNA; 200 ng of total RNA was reverse-transcribed with oligodT primers using the High Capacity cDNA RT Kit (Takara, Japan) in a 20-μl cDNA reaction, as specified by the manufacturer. For quantitative PCR, the template cDNA was added to a 20 μl reaction with SYBR GREEN PCR Master Mix (Applied Biosystems) and 0.2 μM of primer. The amplification was carried out using an ABI Prism 7000 for 40 cycles under the following conditions: (1) an initial denaturation of 95°C for 10 min plus 40 cycles of 95°C for 15 s and (2) 60°C for 1 min. The -fold changes were calculated relative to β-actin (NM_007393.5) using the ΔΔCt method for Sema3A (NM_001243073.1) mRNA analysis. The following primer sets consisted of mouse β-actin: forward, 5′-GTACGCCAACACAGTGCTG-3′; reverse, 5′-CGTCATACTCCTGCTTGCTG-3′ and mouse Sema3A: forward, 5′-AGTGTCCGTACGATCCCAAG-3′; reverse, 5′-GAACAGTGACCACCGTCATC-3′.

Statistical Analysis
--------------------

Differences between experimental groups were evaluated by one-way analysis of variance (ANOVA) using SPSS 17.0 software. Differences with a *P*-value \< 0.05 were considered statistically significant. All experimental data are presented as the mean ± SEM with values from more than three experiments.

Results
=======

Effect of Conditioned Media from Wedelolactone-Treated BMSC on Osteoclastic RAW264.7 Differentiation
----------------------------------------------------------------------------------------------------

To determine the influence of wedelolactone-treated conditioned media from BMSC on osteoclastic differentiation, TRAP activity of osteoclastic RAW264.7 cells was examined after treatment with wedelolactone or conditioned media. As shown in **Figure [1](#F1){ref-type="fig"}**, when RAW264.7 cells were exposed to RANKL for 4 days, TRAP activity was significantly increased. After addition of different conditioned media fractions, which were treated with 2 μg/ml wedelolactone for 3, 6, 9, and 12 days, TRAP activity decreased but to different levels. The decreased amount of TRAP activity was most potent with the addition of the 9-day conditioned medium fraction (**Figure [1](#F1){ref-type="fig"}**). The effects of wedelolactone and 9-day conditioned medium on RAW264.7 cell viability was evaluated.

![**Effect of wedelolactone-treated bone marrow mesenchymal stem cell (BMSC) conditioned media on osteoclastic differentiation of RAW264.7 cells.** Different fractions of wedelolactone-treated BMSC conditioned media were added to RAW264.7 cells. After 4 days of incubation, cultures were fixed, and TRAP activity was assayed. Data are expressed as mean ± SEM of three independent experiments. ^∗^*P* \< 0.05 compared with RANKL-treated cells. ^\#^*P* \< 0.05 compared with wedelolactone-treated cells.](fphar-07-00375-g001){#F1}

The 9-day conditioned medium fraction or wedelolactone at 2 μg/ml did not influence cell viability in the MTT assay (**Figure [2A](#F2){ref-type="fig"}**). However, TRAP staining confirmed that the RANKL-induced increased number of TRAP-stained positive RAW264.7 cells was significantly reduced by incubation with 2 μg/ml wedelolactone. In contrast, treatment with the 9-day conditioned medium fraction led to a more significant decrease in the number of TRAP-stained positive RAW264.7 cells (**Figure [2B](#F2){ref-type="fig"}**).

![**Effect of wedelolactone-treated BMSC conditioned media on RAW264.7 cell proliferation and TRAP activity. (A)** RAW264.7 cells were treated with RANKL, wedelolactone or a 9-day conditioned medium fraction for 4 days. An MTT assay was then performed; *n* = 3, mean ± SEM. **(B)** RAW264.7 cells were incubated with the 9-day conditioned medium fraction for 4 days. RAW264.7 cells were treated with conditions as follows: (a) control; (b) RANKL; (c) RANKL+ wedelolactone; (d) RANKL+ conditioned media for 9-day fraction. Cells were then stained for TRAP by using a TRAP staining kit and imaged at 200×.](fphar-07-00375-g002){#F2}

Effect of Wedelolactone on the Production of Sema3A from BMSC
-------------------------------------------------------------

Sema3A is reported to be produced from osteoblasts ([@B14]). To examine whether wedelolactone stimulated the production of Sema3A from BMSC, qRT-PCR assay was first performed. It was observed that the Sema3A mRNA expression level was upregulated after wedelolactone treatment of BMSC for 9 days (**Figure [3](#F3){ref-type="fig"}**). We added different concentrations of Sema3A antibody to BMSC, and then the activity of ALP, a marker enzyme for osteoblast differentiation, was determined. The increased number of ALP staining-positive BMSC by wedelolactone was reduced by addition of 0.5 or 1 μg/ml Sema3A antibody (**Figure [4A](#F4){ref-type="fig"}**). Morphological changes further confirmed that 1 μg/ml Sema3A antibody blocked the increase in the number of ALP-staining positive BMSC (**Figure [4B](#F4){ref-type="fig"}**). In addition, although 1 μg/ml Sema3A antibody did not affect the reduction in wedelolactone-induced TRAP activity in osteoclastic RAW264.7 cells, the decrease in TRAP activity caused by exposure to the 9-day conditioned medium fraction was reversed by Sema3A antibody (**Figure [4C](#F4){ref-type="fig"}**). These results suggest that wedelolactone-stimulated Sema3A production contributed to the enhancement of ALP activity in BMSC and inhibition of TRAP activity in RAW264.7 cells.

![**Effect of wedelolactone on Sema3A mRNA expression in BMSC.** BMSC were incubated with OS medium containing wedelolactone for 9 days. Total RNA was then isolated. Gene expression was analyzed by rt-qPCR with Sema3A specific primer sets. The expression levels were normalized to the housekeeping genes Actb. Data are expressed as mean ± SEM of three independent experiments. ^∗^*P* \< 0.05 compared with OS-treated control.](fphar-07-00375-g003){#F3}

![**Effects of Sema3A antibody on wedelolactone-induced ALP activity in BMSC and TRAP activity in RAW264.7 cells. (A)** BMSC were cultured in OS medium containing 2 μg/ml wedelolactone and Sema3A antibody for 9 days. The cells were fixed and stained for ALP activity. The data represent the mean ± SEM (*n* = 3). **(B)** ALP staining for BMSC. The cells were treated with conditions as follows: (a) control; (b) OS; (c) OS+wedelolactone; (d) OS+wedelolactone + Sema3A antibody for 4 days. Cells were then stained for ALP by using a ALP staining kit and imaged at 200×. **(C)** TRAP activity in RAW264.7 cells were assayed after the cells were treated with conditioned media for 9-day fraction or Sema3A antibody for 4 days. The data represent the mean ± SEM (*n* = 3). ^∗^*P* \< 0.05 compared with RANKL-treated cells. ^\#^*P* \< 0.05 compared with conditioned media-treated cells.](fphar-07-00375-g004){#F4}

Wedelolactone Regulates Osteoblastogenesis through Sema3A/NRP1/PlexinA1 Pathway-Mediated β-Catenin Activation
-------------------------------------------------------------------------------------------------------------

The activity of Sema3A on osteoblasts is mediated by its binding to the cell surface receptor consisting of Nrp1 and plexinA1. To determine the mechanism by which wedelolactone stimulated the production of Sema3A and subsequently enhanced osteoblastogenesis, the binding of NRP1, plexin-A1, and DAP12 was examined after treatment of BMSC with wedelolactone. Wedelolactone treatment (2 μg/ml) enhanced the binding of NRP1 and plexin-A1, while inhibition of Sema3A by its antibody reduced the formation amount of NRP1-plexin-A1 complex. The formation of the Sema3A-plexin-A1 complex was increased by wedelolactone, but the Sema3A antibody had no effect on the increased amount of the wedelolactone-induced Sema3A-plexin-A1 complex (**Figure [5A](#F5){ref-type="fig"}**).

![**Effect of wedelolactone on the formation of Sema3A/NRP1/PlexinA1 complex and nuclear accumulation of β-catenin in BMSC.** BMSC were seeded in 10-cm plate and treated with or without 2 μg/ml wedelolactone for 9 days. The cells were lysed and subjected to coimmunoprecipitation assays **(A)** or Western blot assays **(B)**. Data are expressed as mean ± SEM of three independent experiments. ^∗^*P* \< 0.05 compared with OS-treated control. ^\#^*P* \< 0.05 compared with wedelolactone-treated cells.](fphar-07-00375-g005){#F5}

The Sema3A signaling pathway is known to induce activation of the Wnt/β-catenin signaling pathway, which is crucial for osteoblast differentiation ([@B15]; [@B27]). Therefore, we focused on nuclear translocation of β-catenin, a transcription factor involved in osteoblast differentiation. When BMSC were treated with wedelolactone, an increase in nuclear accumulation of β-catenin was observed. However, addition of the Sema3A antibody reversed the enhanced wedelolactone-induced nuclear translocation (**Figure [5B](#F5){ref-type="fig"}**). These results suggest that wedelolactone promoted the formation of a Sema3A-NRP1-plexin-A1 complex and subsequently activated β-catenin, which resulted in BMSC differentiation toward osteoblasts.

Involvement of Plexin A1/Nrp1/DAP12 Pathway Activation during Inhibition of Osteoclastogenesis by Wedelolactone
---------------------------------------------------------------------------------------------------------------

In contrast to osteoblasts, the activity of Sema3A on osteoclasts is mediated through inhibition of RANKL-induced formation of the plexinA1-DAP12 complex but without affecting the plexinA1-Nrp1 complex. To examine the impact of wedelolactone on the activation of the Sema3A signaling pathway in osteoclasts, the expression of plexinA1 associated with Nrp1 or DAP12 was determined. As shown in **Figure [6A](#F6){ref-type="fig"}**, addition of RANKL to RAW264.7 cells induced the formation of the plexinA1-DAP12 complex by sequestering plexinA1 from Nrp1, which was consistent with that of previously reported results ([@B14]). The RANKL-induced increase in the amount of DAP12 associated with plexinA1 was downregulated by conditioned media, while the decrease in the amount of Nrp1 associated with PlexinA1 was upregulated by wedelolactone. Furthermore, incubation with the 9-day conditioned medium fraction enhanced the effect of wedelolactone on the plexinA1-NRP1 complex formation, indicating that wedelolactone combined with Sema3A activated the plexinA1-NRP1 pathway. Phospholipase C (PLC)γ2 acts downstream of the plexinA1/NRP1/DAP12 pathway, which participates in osteoclastogenesis. To determine whether PLCγ2 activation was involved in wedelolactone-reduced osteoclastogenesis, phosphorylation of PLCγ2 was monitored. RANKL-induced phosphorylation of PLCγ2 was inhibited by wedelolactone treatment. Addition of the 9-day conditioned medium fraction resulted in a more significant decrease in phosphorylation of PLCγ2 expression (**Figure [6B](#F6){ref-type="fig"}**), indicating that wedelolactone activated the plexin A1//NRP1/DAP12 pathway and subsequently inhibited PLCγ2 activation, thus leading to reduced osteoclastogenesis.

![**Effect of wedelolactone on the formation of NRP1-PlexinA1 and PlexinA1-DAP12 complex, and PLCγ2 activation in RAW264.7 cells.** RAW264.7 cells were treated with RANKL for 4 days in the presence of OS, wedelolactone, BMSC conditioned media (CM1) and wedelolactone-treated conditioned media for 9-day fraction (CM2). Then the cells were lysed and subjected to coimmunoprecipitation assays **(A)** or Western blot assays **(B)**. The data represent the mean ± SEM (*n* = 3). ^∗^*P* \< 0.05 compared with untreated control. ^\#^*P* \< 0.05 compared with RANKL+OS group.](fphar-07-00375-g006){#F6}

Discussion
==========

Bone homeostasis requires the coupling of bone resorption and bone formation. An excess of osteoclastic bone resorption over osteoblastic bone formation can result in bone-related diseases such as osteoporosis. Osteoblasts and osteoclasts are coupled by various coupling factors, which maintain bone remodeling homeostasis. Some coupling factors such as sclerostin, which is produced from osteoclastic precursors, reduce bone formation. Some osteoclast-derived coupling factors such as sphingosine 1-phosphate, however, induced osteoblast differentiation ([@B10]). Interestingly, Sema3A, as a dual function coupling factor, which is secreted by osteoblastic cells, inhibits osteoclastic activity and at the same time, promotes osteoblastic differentiation ([@B14]). It appears to be useful for preventing bone loss. Mice lacking Sema3A were found to have undergone bone loss ([@B9]). Therefore, regulation of Sema3A and its corresponding signaling pathway may be helpful for treatment of osteoporosis ([@B2]). In cultured chick dorsal root ganglion neurons, several small molecular drugs have been reported to interfere with Sema3A activity through inhibition of Sema3A-induced growth cone collapse ([@B19]; [@B18]). However, it has not been shown that small molecular compounds stimulate Sema3A activity to prevent of bone loss. In this study, wedelolactone, a compound isolated from *Ecliptae herba*, stimulated Sema3A mRNA expression, indicating that the wedelolactone's mechanism of action appeared to be promotion of Sema3A activity, distinct from the known Sema3A activity inhibitor.

Wedelolactone is a component isolated from *Ecliptae herba*, which is widely used in China to strengthen bones. Our previous study showed that wedelolactone inhibited RANKL-induced osteoclast differentiation ([@B21]). In this study, we further investigated the role of wedelolactone in the coupling of osteoclast and osteoblasts during earlier precursor stages. Mature osteoblastic cells are derived from BMSC, which secret various factors, including Wnt and BMP, to induce differentiation toward osteoblasts ([@B17]; [@B15]). Upon 9 days of treatment with wedelolactone, the mRNA expression levels of Sema3A increased. A 9-day conditioned medium fraction was further confirmed to contain biologically active Sema3A protein, as confirmed by inhibition of ALP activity by Sema3A antibody. However, fractions obtained from more or less than 9 days of incubation (such as 6 or 12 days) had no obvious inhibitory effect on TRAP activity of RAW264.7 cells, suggesting that Sema3A derived from BMSC was induced by wedelolactone at the 9-day differentiation stage. These results were similar to those from a previous study of upregulated Sema3A mRNA expression from calvarial cells stimulated by 1α, 25 (OH)~2~D~3~ and PGE~2~ ([@B14]).

In osteoblasts, Sema3A was shown to associate with plexin A1 and Nrp1, which induces the downstream activation of the Wnt pathway ([@B25]). Sema3A production from wedelolactone-stimulated BMSC resulted in the formation of the plexin A1-Nrp1 and plexin A1-Sema3A complexes, indicating that wedelolactone-induced osteoblast differentiation was mediated through the Sema3A/Plexin A1/Nrp1 pathway. Blockage of active Sema3A by addition of Sema3A antibody reversed the increase in the amount of the plexin A1-Nrp1 complex but had no effect on the amount of the plexin A1-Sema3A complex, indicating that addition of Sema3A antibody was not enough to block the binding of plexin A1 with Sema3A; wedelolactone, however, was able to promote the formation of the plexin A1-Sema3A and plexin A1-Nrp1 complexes. β-Catenin has been shown to be a key transcription factor of Wnt pathway, which is responsible for osteoblastogenesis ([@B6]). A previous study reported that Wnt3a-induced nuclear accumulation of β-catenin was suppressed in Sema3A^-/-^ calvarial cells ([@B14]). In this study, wedelolactone treatment resulted in the nuclear accumulation of β-catenin. However, neutralization of Sema3A by addition of the Sema3A antibody partially inhibited nuclear accumulation of β-catenin, indicating that wedelolactone-stimulated β-catenin activation through nuclear translocation acted downstream of the plexin A1-Nrp1 complex.

In osteoclasts, RANKL has been reported to downregulate Nrp1 expression, resulting in osteoclast differentiation via sequestration of plexin A1 from Nrp1 with formation of plexin A1-DAP12 complex ([@B30]; [@B31]). In this study, the RANKL-induced formation of the plexin A1-DAP12 complex in osteoclastic RAW264.7 cells was inhibited by conditioned media and wedelolactone, while the amount of plexin A1 associated with Nrp1 increased. This result was consistent with the previous study that reported Sema3A binding to the plexin A1-Nrp1 complex followed by suppression of RANKL-induced osteoclast differentiation via a reduction in the formation of the plexin A1-DAP12 complex ([@B14]). Addition of Sema3A antibody reversed the effects of conditioned media on the formation of the plexin A1-Nrp1 complex and PLCγ2 activation, since PLCγ2 phosphorylation was indicated to be related to Sema3A signaling ([@B22]; [@B7]; [@B8]). In the current study, in addition to the role of Sema3A in the conditioned media, wedelolactone was also implicated in direct mediation of the Sema3A/plexin A1/Nrp1 pathway instead of the plexin A1/DAP12 pathway. However, we do not know whether the action of wedelolactone did or did not directly interfere with the interaction of the Sema3A/plexin A1/Nrp1 pathway. Additional studies concerning the target for wedelolactone on osteoblasts and osteoclasts are needed. A previous study showed that wedelolactone inhibited breast cancer-induced osteoclastogenesis through inhibition of IκBα phosphoration ([@B16]). NF-κB pathway acts downstream of Sema3A signaling. The upregulated expression of Nrp1 by wedelolactone might be attributed to inhibition of the NF-κB pathway.

Of note, quite a few studies indicate that plexins and semphorins family proteins have multiple roles. Genetic as well as pharmacological *in vivo* experiments have indicated that therapeutic interventions with Sema3A may also cause adverse effects ([@B12]). Wedelolactone is suggested to regulate osteoblasts and osteoclasts by stimulating Sema3A activity. Concurrently, wedelolactone was able to alter other pathways such as the NF-κB pathway. This multi-target effect of wedelolactone might prevent the side effects of Sema3A.

Conclusion
==========

In the present study, we demonstrated that effective stimulation of Sema3A production from BMSC by wedelolactone contributed to osteogenesis. Wedelolactone and wedelolactone-treated 9-day conditioned medium fraction from BMSC exerted inhibitory effects on osteoclastogenesis via Sema3A/plexin A1/Nrp1 signaling.

In BMSC, wedelolactone induced the binding of plexin A1/Nrp1 and activated downstream molecules of Wnt/β-catenin pathway.

In osteoclastic RAW264.7 cells, the plexin A1-DAP12 complex was sequestered by wedelolactone with subsequent inhibition of PLCγ2 phosphorylation.
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